A carregar...
Modulation of genomic and epigenetic end-points by celecoxib
Celecoxib, a nonsteroidal anti-inflammatory drug that selectively targets cyclooxygenase-2, is a promising cancer chemopreventive agent. However, safety concerns have been raised in clinical trials evaluating its ability to prevent colorectal adenomas. The rationale for the herein reported studies w...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6154745/ https://ncbi.nlm.nih.gov/pubmed/30263093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26062 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|